{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:43:35Z","timestamp":1781585015632,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.vaccine.2017.03.008","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T22:15:16Z","timestamp":1492726516000},"page":"2993-2998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule"],"prefix":"10.1016","volume":"35","author":[{"given":"Abhijeet","family":"Anand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie A.","family":"Molodecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Pallansch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland W.","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.03.008_b0005","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1126\/science.aad7294","article-title":"Eradicating polio","volume":"350","author":"Adams","year":"2015","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.vaccine.2017.03.008_b0010","unstructured":"The Global Polio Eradication Initiative. Polio eradication and endgame strategic plan 2013\u20132018. Geneva, Switzerland; 2013."},{"key":"10.1016\/j.vaccine.2017.03.008_b0015","first-page":"1","article-title":"Meeting of the strategic advisory group of experts on immunization, November 2013 \u2013 conclusions and recommendations","volume":"89","author":"World Health Organization","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2017.03.008_b0020","doi-asserted-by":"publisher","first-page":"934","DOI":"10.15585\/mmwr.mm6535a3","article-title":"Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - worldwide, 2016","volume":"65","author":"Hampton","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.03.008_b0025","first-page":"201","article-title":"Meeting of the strategic advisory group of experts on immunization, April 2012 - conclusions and recommendations","author":"World Health Organization","year":"2012","journal-title":"Wkly Epidemiol Rec."},{"key":"10.1016\/j.vaccine.2017.03.008_b0030","first-page":"145","article-title":"Polio vaccines: WHO position paper \u2013 March 2016","volume":"12","author":"World Health Organization","year":"2016","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2017.03.008_b0035","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa1202541","article-title":"Priming after a fractional dose of inactivated poliovirus vaccine","volume":"368","author":"Resik","year":"2013","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2017.03.008_b0040","series-title":"An introduction to the bootstrap","author":"Efron","year":"1993"},{"key":"10.1016\/j.vaccine.2017.03.008_b0045","series-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2015"},{"key":"10.1016\/j.vaccine.2017.03.008_b0050","first-page":"e110","article-title":"Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines","volume":"16","author":"Cadorna-Carlos","year":"2012","journal-title":"Int J Inf Dis: IJID: Off Publ Int Soc Inf Dis"},{"key":"10.1016\/j.vaccine.2017.03.008_b0055","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S1473-3099(11)70190-6","article-title":"Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6\u20139 months in Moradabad, India: a community-based, randomised controlled trial","volume":"12","author":"Estivariz","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.008_b0060","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.vaccine.2014.11.025","article-title":"Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba","volume":"33","author":"Resik","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.008_b0065","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/0264-410X(92)90039-M","article-title":"Immune response of infants to inactivated poliovirus vaccine injected intradermally","volume":"10","author":"Samuel","year":"1992","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.008_b0070","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S0264-410X(97)00293-4","article-title":"Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine","volume":"16","author":"Nirmal","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.008_b0075","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1086\/651611","article-title":"Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba","volume":"201","author":"Resik","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.008_b0080","doi-asserted-by":"publisher","first-page":"6816","DOI":"10.1016\/j.vaccine.2015.09.039","article-title":"Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial","volume":"33","author":"Anand","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.008_b0085","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1056\/NEJMoa0909383","article-title":"Fractional doses of inactivated poliovirus vaccine in Oman","volume":"362","author":"Mohammed","year":"2010","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2017.03.008_b0090","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1016\/S0140-6736(15)00237-8","article-title":"Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial","volume":"386","author":"Sutter","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.03.008_b0095","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S0140-6736(16)00703-0","article-title":"Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial","volume":"388","author":"Asturias","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.03.008_b0100","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S1473-3099(15)00488-0","article-title":"Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial","volume":"16","author":"Saez-Llorens","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.008_b0105","unstructured":"World Health Organization. Summary of the April 2016 meeting of the strategic advisory group of experts on immunization (SAGE). Geneva, Switzerland; 2016. p. 1\u2013-4."},{"key":"10.1016\/j.vaccine.2017.03.008_b0110","doi-asserted-by":"publisher","first-page":"859","DOI":"10.15585\/mmwr.mm6533a5","article-title":"Fractional-dose inactivated poliovirus vaccine immunization campaign \u2013 Telangana State, India, June 2016","volume":"65","author":"Bahl","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.03.008_b0120","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.15585\/mmwr.mm6444a5","article-title":"Global routine vaccination coverage, 2014","volume":"64","author":"Subaiya","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.03.008_b0115","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.1016\/j.vaccine.2015.06.071","article-title":"Needle-free jet injector intradermal delivery of fractional dose inactivated poliovirus vaccine: association between injection quality and immunogenicity","volume":"33","author":"Resik","year":"2015","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17303146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17303146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T10:54:13Z","timestamp":1535885653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17303146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":24,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0264410X17303146"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.008","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}